Aratana Therapeutics (PETX) Misses Q4 EPS by 15c, Beats on Revenues; Offers FY18 Financial Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. SNDK
6. HTFL
7. ADYEN:NA
8. DVLT
9. ADYYF
10. WDAY

Go back to Aratana Therapeutics (PETX) Misses Q4 EPS by 15c, Beats on Revenues; Offers FY18 Financial Guidance

CL King Upgrades Aratana Therapeutics (PETX) to Buy Citing Enticing Risk/Reward

March 12, 2018 6:58 AM EDT

CL King upgraded Aratana Therapeutics (NASDAQ: PETX) from Neutral to Buy.

For an analyst ratings summary and ratings history on Aratana Therapeutics click here. For more ratings news on Aratana Therapeutics click here.

Shares of Aratana Therapeutics closed at $4.26 Friday.

... More